CANVA
30.7.2024 05:31:28 CEST | Business Wire | Press release
Canva, a world leader in visual communication with more than 190 million monthly active users, today announced plans to acquire Leonardo.AI. As one of Australia’s fastest-growing startups, and a leading generative AI content and research company, Leonardo.AI is empowering millions of people to bring their ideas to life through production-quality images and videos. The acquisition complements Canva's offering and enhances the company’s vision to build a world-class suite of visual AI tools, marking this as an important milestone in its AI journey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729977410/en/
Canva will acquire Leonardo.AI, a leading generative AI content and research company (Graphic: Business Wire)
As AI continues to shape the future of work and visual communication, the acquisition will accelerate Canva’s investment in continued research and development while bringing Leonardo’s cutting-edge foundational model to Canva’s community worldwide. From creating assets for marketing and advertising campaigns, to visualizing stunning interior concepts, refining mockups, and producing dynamic videos, Leonardo’s technology has been used to produce more than one billion images in the last 18 months.
For Leonardo.AI this is an opportunity to produce new levels of AI innovation while also growing the organisation’s scale. With Canva’s support, the company’s current trajectory will be supercharged to build an even more creative-centric generative AI platform globally.
“We’re thrilled to welcome Leonardo.AI to Canva - two Australian companies joining forces to bring world-first breakthroughs in AI and creativity," said Cameron Adams, co-founder and Chief Product Officer of Canva. “This field is constantly evolving, and Leonardo’s technical leadership and community impact can’t be overstated. Bringing our worlds together will accelerate each of our teams' work, taking us from strength to strength, and we can’t wait to get started.”
World Leading Generative AI Capabilities
Founded in late 2022, Leonardo’s foundational model empowers millions of people to turn ideas into production-quality visual assets with unprecedented control, speed and style consistency. Creators can generate images in any chosen aesthetic in seconds with simple prompts, create videos, sketch with AI, and custom-train models with their own datasets.
Leonardo's new foundational model, Phoenix, takes creator control to the next level, with unprecedented prompt adherence, coherent, accurate text in images and the ability to generate production-ready assets in one shot.
“Today marks the start of a new chapter which will accelerate the pace we innovate at Leonardo.Ai,” said JJ Fiasson, Founder and CEO, Leonardo.AI. Joining the Canva family means we can invest more deeply in scaling our AI research efforts globally, and move even faster to deliver new features and functionality to creatives worldwide.”
In less than two years since launching, Leonardo.AI has amassed more than 19 million registered users and is used across a wide variety of industries including advertising, marketing, design, entertainment, architecture, fashion, e-commerce and education. The joint effort with Canva will produce new levels of AI technology to not only engage, but to also grow Leonardo’s fast growing user base.
From hobbyists to film directors, architects, and professional designers, Leonardo’s technology delivers advanced creative control that pushes the boundaries of what’s possible in generative AI, while remaining intuitive and accessible. Its models can generate stunning images in styles ranging from strikingly realistic photos to character portraits, anime, painterly styles, and more, while its AI video generation tools can bring almost any concept to dynamic life.
Reimagining Visual Communication
Canva’s recent Visual Economy Report shows that the need for effective, efficient, and compelling visual communication has surged dramatically. AI is now playing an increasingly important role in elevating both productivity and creativity at work. From marketing teams scaling global campaigns by instantly generating ad creative for specific audiences, to designers creating initial drafts and storyboards, generative artificial intelligence is changing the way work gets done.
Leonardo’s world-class technology and foundational model will supercharge Canva’s mission to empower every kind of professional to turn their ideas into designs in an instant, leading to faster, more innovative, and more compelling visual communication.
Leonardo's technology will complement Canva’s Magic Studio, the company’s suite of AI tools, which has been used more than 7 billion times since it launched in 2023. To date, Canva users have elevated their design and creative output leveraging Magic Studio for everything from summarising documents to creating images and turning brainstorm whiteboards into fully-fledged presentations.
Supercharging Canva’s AI Journey
Canva will continue to invest in Leonardo's standalone platform while integrating its technology throughout the company’s suite of Magic Studio products. Working with Leonardo’s team of 120 high-caliber researchers, engineers, and designers will also bolster Canva’s research and development capabilities as the company continues to invest in long-term innovation opportunities.
Acquisitions have played an important role in elevating and accelerating Canva’s technology over the last decade. The acquisition of Leonardo is the company’s 8th acquisition, joining Affinity (2024), Flourish (2022), Kaleido (2021), Smartmockups (2021), Pexels (2019), Pixabay (2019) and Zeetings (2018).
For more details about the acquisition, see Canva Co-Founder Cameron Adams blog post and Leonardo.Ai’s CEO JJ Fiasson’s blog post, respectively.
About Canva
Launched in 2013, Canva is a free online visual communications and collaboration platform with a mission to empower everyone in the world to design. Featuring a simple drag-and-drop user interface and a vast range of templates ranging from presentations, documents, websites, social media graphics, posters, apparel to videos, plus a huge library of fonts, stock photography, illustrations, video footage, and audio clips, anyone can take an idea and create something beautiful.
About Leonardo.Ai
Leonardo.Ai is one of Australia’s fastest-growing startups, democratising creativity with its generative AI content production platform. Since launching in 2022, the company has amassed more than 19 million users worldwide, who have generated over one billion images. Leonardo.Ai is currently being used by both hobbyists and professionals across creative industries such as advertising and marketing, design and architecture, film, fashion, photography, e-commerce, education, and more.
Downloadable Assets
Click here
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729977410/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom